Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults

Simple item page
dc.contributor.authorByakika-Kibwika, Pauline
dc.contributor.authorLamorde, Mohammed
dc.contributor.authorLwabi, Peter
dc.contributor.authorNyakoojo, Wilson B.
dc.contributor.authorOkaba-Kayom, Violet
dc.contributor.authorMayanja-Kizza, Harriet
dc.contributor.authorBoffito, Marta
dc.contributor.authorKatabira, Elly
dc.contributor.authorBack, David
dc.contributor.authorKhoo, Saye
dc.contributor.authorMerry, Concepta
dc.date.accessioned2022-01-12T09:11:11Z
dc.date.available2022-01-12T09:11:11Z
dc.date.issued2011
dc.description.abstractWe aimed to assess cardiac conduction safety of coadministration of the CYP3A4 inhibitor lopinavir/ritonavir (LPV/r) and the CYP3A4 substrate artemether-lumefantrine (AL) in HIV-positive Ugandans. Methods. Open-label safety study of HIV positive adults administered single-dose AL (80/400 mg) alone or with LPV/r (400/100 mg). Cardiac function was monitored using continuous electrocardiograph (ECG). Results. Thirty-two patients were enrolled; 16 taking LPV/r -based ART and 16 ART naıve. All took single dose AL. No serious adverse events were observed. ECG parameters in milliseconds remained within normal limits. QTc measurements did not change significantly over 72 hours although were higher in LPV/r arm at 24 (424 versus 406; P = .02) and 72 hours (424 versus 408; P = .004) after AL intake. Conclusion. Coadministration of single dose of AL with LPV/r was safe; however, safety of six-dose AL regimen with LPV/r should be investigated.en_US
dc.identifier.citationByakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, WB, Okaba-Kayom, V., Mayanja-Kizza, H., ... & Merry, C. (2011). Cardiac conduction safety during coadministration of artemether-lumefantrine and lopinavir / ritonavir in HIV-infected Ugandan adults. Chemotherapy research and practice , 2011. doi:10.1155/2011/393976en_US
dc.identifier.other10.1155/2011/393976
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1207
dc.language.isoenen_US
dc.publisherChemotherapy research and practiceen_US
dc.subjectCardiac Conduction Safetyen_US
dc.subjectArtemether-Lumefantrineen_US
dc.subjectLopinavir/Ritonaviren_US
dc.subjectHIV-Infected Ugandan Adultsen_US
dc.titleCardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adultsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cardiac Conduction Safety during Coadministration of rs.pdf
Size:
523.88 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences